A Case of Recurrent Hepatocellular Carcinoma Acquiring Complete Remission of Target Lesion With Treatment With Traditional Chinese Medicine
- PMID: 27444311
- PMCID: PMC5739135
- DOI: 10.1177/1534735416660617
A Case of Recurrent Hepatocellular Carcinoma Acquiring Complete Remission of Target Lesion With Treatment With Traditional Chinese Medicine
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Although surgery is known as the most promising radical treatment, a high recurrent or metastatic rate after surgery has limited its clinical efficacy. Sorafenib, a target agent, has seemed to be the only option for metastatic HCC patients to date, but none of clinical trials showed it could prolong the overall survival (OS) of advanced HCC to 1 year. How to prolong the OS and improve cure rate of HCC patients is still beset with difficulties. This report presents a rare case of recurrent HCC patient with complete regression of target lesion with 2 years of Chinese herbal treatment. A 64-year-old Chinese man with hepatitis B virus-associated chronic hepatitis presented HCC has been clinically diagnosed tumor relapse and omentum metastasis with computed tomography and α-fetoprotein blood test 4 months after surgery. It was decided the patient would receive traditional Chinese medicine treatment because of poor prognosis. After approximately 2 years of treatment, recurrent hepatic tumor and omentum metastasis have been found in complete regression. The patient remains alive over 31 months after relapse.
Keywords: activities; complete remission; recurrent hepatocellular carcinoma; spontaneous regression; traditional Chinese medicine.
Conflict of interest statement
Figures






Similar articles
-
Preventive and therapeutic role of traditional Chinese herbal medicine in hepatocellular carcinoma.J Chin Med Assoc. 2015 Mar;78(3):139-44. doi: 10.1016/j.jcma.2014.09.003. Epub 2014 Oct 25. J Chin Med Assoc. 2015. PMID: 25447209 Review.
-
Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma.J Ethnopharmacol. 2013 Oct 7;149(3):601-12. doi: 10.1016/j.jep.2013.07.030. Epub 2013 Aug 1. J Ethnopharmacol. 2013. PMID: 23916858 Review.
-
Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma.Phytomedicine. 2019 Sep;62:152930. doi: 10.1016/j.phymed.2019.152930. Epub 2019 May 11. Phytomedicine. 2019. PMID: 31128485 Clinical Trial.
-
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.Clin Mol Hepatol. 2015 Sep;21(3):287-94. doi: 10.3350/cmh.2015.21.3.287. Epub 2015 Sep 30. Clin Mol Hepatol. 2015. PMID: 26527250 Free PMC article.
-
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China.Integr Cancer Ther. 2018 Sep;17(3):902-911. doi: 10.1177/1534735418775819. Epub 2018 May 18. Integr Cancer Ther. 2018. PMID: 29775121 Free PMC article.
Cited by
-
Systematic Elucidation of the Potential Mechanisms of Core Chinese Materia Medicas in Treating Liver Cancer Based on Network Pharmacology.Evid Based Complement Alternat Med. 2020 Apr 24;2020:4763675. doi: 10.1155/2020/4763675. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32382293 Free PMC article.
-
Bie Jia Jian Pill Combined with Bone Mesenchymal Stem Cells Regulates microRNA-140 to Suppress Hepatocellular Carcinoma Stem Cells.Int J Stem Cells. 2021 Aug 30;14(3):275-285. doi: 10.15283/ijsc20157. Int J Stem Cells. 2021. PMID: 33632990 Free PMC article.
-
Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.Trials. 2020 Jun 5;21(1):482. doi: 10.1186/s13063-020-04395-y. Trials. 2020. PMID: 32503608 Free PMC article.
-
Recent Advances in Anti-Metastatic Approaches of Herbal Medicines in 5 Major Cancers: From Traditional Medicine to Modern Drug Discovery.Antioxidants (Basel). 2021 Mar 27;10(4):527. doi: 10.3390/antiox10040527. Antioxidants (Basel). 2021. PMID: 33801741 Free PMC article. Review.
-
YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial.Trials. 2021 Oct 14;22(1):701. doi: 10.1186/s13063-021-05650-6. Trials. 2021. PMID: 34649610 Free PMC article.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. - PubMed
-
- Llovet JM, Fuster J, Bruix J. Prognosis of hepatocellular carcinoma. Hepatogastroenterology. 2002;49(43):7-11. - PubMed
-
- Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. - PubMed
-
- Thomas MB, O’Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008;15:1008-1014. - PubMed
-
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical